ACT-774312 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bilateral Nasal Polyposis
Conditions
Bilateral Nasal Polyposis
Trial Timeline
Oct 19, 2018 → Dec 1, 2020
NCT ID
NCT03688555About ACT-774312 + Placebo
ACT-774312 + Placebo is a phase 2 stage product being developed by Idorsia for Bilateral Nasal Polyposis. The current trial status is completed. This product is registered under clinical trial identifier NCT03688555. Target conditions include Bilateral Nasal Polyposis.
What happened to similar drugs?
1 of 2 similar drugs in Bilateral Nasal Polyposis were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03688555 | Phase 2 | Completed |
Competing Products
3 competing products in Bilateral Nasal Polyposis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGF166 | Novartis | Phase 1/2 | 32 |
| Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7% | Ocular Therapeutix | Approved | 37 |
| cataract surgery | GenZum Life Sciences | Phase 3 | 30 |